Clinical Trials Browser

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT03911388 2026-04-13

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Choroid Plexus Carcinoma, Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Cerebellar Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Nervous System Diseases, Nervous System Neoplasms, Oligodendroglioma, Virus Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor

Clinical Trials

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

SC9/ABX

WinGlio-ipi

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

Study of Pembrolizumab and M032 (NSC 733972)

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Natural Progesterone for the Treatment of Recurrent Glioblastoma

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

M032-HSV-1

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma

OLFGBM

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas